Biotech Values

[genisi]

VRTX/Cystic Fibrosis

VX-770 will be studied in patients bearing the G551D mutation on at least one allele (2 phase III trials), and also in homozygous for the higher prevalence F508del mutation (phase II trial). So VX-770 still has potential beyond G551D patients population.
On economic factors I have commented elsewhere (http://siliconinvestor.advfn.com/readreplies.aspx?msgid=25673345&nonstock=False&subjectid=7368) and I would add another potential benefit: it could lead to reductions in need for inhaled antibiotics and mucolytics.